GETTING RID OF THE LITTLE GREATER THAN SIGNS

November 19, 2004

dEAR Jim,

Every time I send an e-mail that I recieved I select all, copy,

reply to all, paste at the top, delete the ones that have the greater thans

on the left and leave all the stuff about who it was from and to at the

bottom and then fill out whoever i want it ot go to this time. i wasn't

aware that there is a way to set your computer to get rid of theme but there

needs to be. I dont' know why we need them. Sometimes if you're forwarding

it they dont' show up but i don't know what difference that makes. but once

something gets forwarded enought times you end up wiht more greater signs

taking up space than you do script. this ha sbeen a good week-the media is

starting to take up this issue of genocidal pharmeceuticals -

sandra lance, d.c.--- Original Message -----

From: " Jim " <mofunnow@...>

Sent: Friday, November 19, 2004 7:29 PM

Subject: Re: Drug firms stock prices hit by safety scares

!!! ( London f.t.s.e )

>

> Hi ,

>

> I cannot seem to get rid of these dang >'s. I have set (I think) my

outlook

> express

> to not put them there. I will keep trying.

>

> Your best bet for articles without the >'s is the original which was sent

by

> and titled

> " Subject: Drug firms stock prices hit by safety scares

!!! "

>

> Best,

>

> Jim

>

> Drug firms stock prices hit by safety scares

> !!!

> > > ( London f.t.s.e )

> > >

> > > >

> > > > http://www.network54.com/Forum/message?

> > > > forumid=281849 & messageid=1100892378

> > > >

> > > > Drug firms hit by safety scares

> > > >

> > > > Concerns about the health of drug companies after a warning from a

> > > > whistleblower at the US Food and Drug Administration (FDA) have hit

> > > > shares.

> > > > The FDA's Dr Graham warned that certain drugs from

> > > > AstraZeneca, Roche and GlaxoKline (GSK) needed further

> > > > regulatory attention.

> > > >

> > > > AstraZeneca responded during the afternoon on Friday by insisting

> > > > the FDA had said it had no safety concerns.

> > > >

> > > > AstraZeneca fell more than 10%, and GSK almost 4% by late afternoon

> > > > in London.

> > > >

> > > > Dr Graham's warning came as he was speaking to the US Senate on

> > > > Thursday on Merck's banned drug Vioxx.

> > > >

> > > > During his talk he cast doubt on the FDA's competence.

> > > >

> > > > Dr Graham's list of drugs requiring further scrutiny from the Food

> > > > and Drug Administration included AstraZeneca's Crestor,

> > > > GlaxoKline's Serevent and Roche's Accutane.

> > > >

> > > > In response, AstraZeneca said during Friday afternoon: " We have been

> > > > assured today at senior levels in the FDA that there is no concern

> > > > in relation to Crestor's safety " .

> > > >

> > > > Glaxo says its quest is to " enable people to do more,

> > > > feel better and live longer "

> > > >

> > > > Merrill Lynch, the US investment bank, noted that neither asthma

> > > > drug, Serevent, nor acne drug, Accutane, accounted for a big share

> > > > of their makers' profits.

> > > >

> > > > But it expects cholesterol-cutting Crestor to make up 12% of

> > > > AstraZeneca's sales by 2008.

> > > >

> > > > A forthcoming article in the US American Medical Association Review

> > > > is expected to cover the drug's kidney side-effects.

> > > >

> > > > Safe and effective

> > > >

> > > > Unethical behaviour by drug companies has been in the spotlight

> > > > after New York attorney general Eliot Spitzer fined GSK for

> > > > allegedly suppressing negative clinical trial data on Seroxat.

> > > >

> > > > In a statement issued on Thursday GSK said it stands behind

> > > > Serevent, saying it is " safe and effective " .

> > > >

> > > > It added that: " any issues concerning mortality...have been fully

> > > > considered by the FDA, resulting in a black box warning that was

> > > > included in the medicine's label " in August 2003.

> > > >

> > > > http://news.bbc.co.uk/1/hi/business/4025001.stm

>

November 19, 2004